Texas Biotech Exceeds Alzheimer's Trial Enrollment Target
Texas Biotech Exceeds Alzheimer's Trial Enrollment Target
Source: investorideas.com
Page 21 - Cassava Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cassava Sciences Today - Breaking & Trending Today
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected...
Source: marketscreener.com
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
07.11.2023 - Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week ...
Source: wallstreet-online.de
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease -November 06, 2023 at 09:16 am EST
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end...
Source: marketscreener.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. . Such investors are advised to contact Robert S. Willoughby at...
Source: marketscreener.com